Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity.
Wohl DA, Pilcher CD, Evans S, Revuelta M, McComsey G, Yang Y, Zackin R, Alston B, Welch S, Basar M, Kashuba A, Kondo P, Martinez A, Giardini J, Quinn J, Littles M, Wingfield H, Koletar SL; Adult AIDS Clinical Trials Group A5129 Team. Wohl DA, et al. Among authors: koletar sl. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):274-8. doi: 10.1097/00126334-200403010-00008. J Acquir Immune Defic Syndr. 2004. PMID: 15076242 Clinical Trial.
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy.
Goldman M, Zackin R, Fichtenbaum CJ, Skiest DJ, Koletar SL, Hafner R, Wheat LJ, Nyangweso PM, Yiannoutsos CT, Schnizlein-Bick CT, Owens S, Aberg JA; AIDS Clinical Trials Group A5038 Study Group. Goldman M, et al. Among authors: koletar sl. Clin Infect Dis. 2004 May 15;38(10):1485-9. doi: 10.1086/420749. Epub 2004 Apr 28. Clin Infect Dis. 2004. PMID: 15156489
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team. Gulick RM, et al. Among authors: koletar sl. JAMA. 2006 Aug 16;296(7):769-81. doi: 10.1001/jama.296.7.769. JAMA. 2006. PMID: 16905783 Clinical Trial.
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.
Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA; A5030 Study Team. Wohl DA, et al. HIV Clin Trials. 2009 May-Jun;10(3):143-52. doi: 10.1310/hct1003-143. HIV Clin Trials. 2009. PMID: 19632953 Free PMC article. Clinical Trial.
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.
Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C; ACTG 5267 Study Team. Dooley KE, et al. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):455-62. doi: 10.1097/QAI.0b013e3182410503. J Acquir Immune Defic Syndr. 2012. PMID: 22126739 Free PMC article. Clinical Trial.
Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the United States, 2000-2010.
Yanik EL, Napravnik S, Ryscavage P, Eron JJ, Koletar SL, Moore RD, Zinski A, Cole SR, Hunt P, Crane HM, Kahn J, Mathews WC, Mayer KH, Taiwo BO; Center for Aids Research Network of Integrated Clinical Systems (CNICS) Cohort Study. Yanik EL, et al. Among authors: koletar sl. J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):216-20. doi: 10.1097/QAI.0b013e31828d69f1. J Acquir Immune Defic Syndr. 2013. PMID: 23446495 Free PMC article.
132 results